Screener
Kymera Therapeutics KYMR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
FAQ
- What is Kymera Therapeutics's EBITDA margin?
- Kymera Therapeutics (KYMR) reported EBITDA margin of -325.7% in Q2 2026.
- How has Kymera Therapeutics's EBITDA margin changed year-over-year?
- Kymera Therapeutics's EBITDA margin increased by 52.1% year-over-year, from -679.4% to -325.7%.
- What is the long-term trend for Kymera Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Kymera Therapeutics's EBITDA margin has grown at a 46.1% compound annual growth rate (CAGR), from -130.9% to -869.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Kymera Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude